SSA
EWTX icon

Schonfeld Strategic Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.12M Buy
99,075
+39,749
+67% +$1.15M 0.02% 650
2025
Q4 		$1.47M Buy
59,326
+7,337
+14% +$147K 0.01% 974
2025
Q3 		$843K Sell
51,989
-115,351
-69% -$1.64M ﹤0.01% 1467
2025
Q2 		$2.19M Sell
167,340
-111,633
-40% -$1.61M 0.01% 927
2025
Q1 		$6.14M Buy
278,973
+10,464
+4% +$275K 0.04% 468
2024
Q4 		$7.17M Sell
268,509
-277,037
-51% -$8.82M 0.04% 397
2024
Q3 		$14.6M Buy
545,546
+467,412
+598% +$9.3M 0.1% 215
2024
Q2 		$1.41M Sell
78,134
-206,466
-73% -$3.6M 0.01% 1056
2024
Q1 		$5.19M Sell
284,600
-34,500
-11% -$548K 0.03% 630
2023
Q4 		$3.49M Buy
319,100
+202,200
+173% +$1.42M 0.02% 618
2023
Q3 		$670K Buy
116,900
+3,900
+3% +$26.5K 0.01% 1138
2023
Q2 		$876K Buy
113,000
+100,782
+825% +$850K 0.01% 1022
2023
Q1 		$81.5K Buy
+12,218
New +$113K ﹤0.01% 1725

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Schonfeld Strategic Advisors's EWTX Position: Q1 2026 in Review

Schonfeld Strategic Advisors increased its Edgewise Therapeutics (EWTX) stake by 67% in Q1 2026, buying an estimated $1.15M and bringing the position to 99,075 shares worth $3.12M. The position accounts for 0.02% of the portfolio, ranked #650.

Schonfeld Strategic Advisors first reported a position in EWTX in Q1 2023 and has held it in 13 quarters since. The position peaked at $14.6M in Q3 2024. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Schonfeld Strategic Advisors held 99,075 shares of Edgewise Therapeutics worth $3.12M as of Q1 2026.
  • Schonfeld Strategic Advisors bought 39,749 Edgewise Therapeutics shares in Q1 2026, an estimated $1.15M.
  • Edgewise Therapeutics made up 0.02% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #650 holding.
  • Schonfeld Strategic Advisors first reported a position in Edgewise Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Schonfeld Strategic Advisors's Edgewise Therapeutics position peaked at $14.6M in Q3 2024.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.